Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Covance Not Hurrying to Build More China Facilities

publication date: Oct 31, 2008

Following the collapse of its Joint Venture arrangement with WuXi PharmaTech, Covance will build its own China CRO facilities, but the company does not feel any great pressure to get the job done quickly. The reason? China’s current cost advantage will soon disappear, as wages for scientists in China approach those in the west, according to Joe Herring, CEO of Covance. Covance does $1.5 billion worth of CRO business around the world. Apparently, it does not feel as though it is losing a great deal of contracts to its China-based competitors. More details...

Stock Symbols: (NYSE: CVD) (NYSE: WX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here